Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RBP4 | P02753 | 2/20 | 0.43 |
| ▸ | RARA | P10276 | 2/20 | 0.43 |
| ▸ | RARB | P10826 | 2/20 | 0.43 |
| ▸ | RARG | P13631 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300149 | 0.84 | TRPV4 (0.44) | LMNAMAPK1HTTKDM4ETRPV4 | |
| SCHEMBL16579349 | 0.84 | TRPV4 (0.44) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL803017 | 0.83 | TRPV4 (0.56) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL12804704 | 0.81 | NR3C1 (0.45) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL25952455 | 0.80 | LMNA (0.48) | LMNAMAPK1HTTKDM4EGAA | |
| Hydrochloric Acid SCHEMBL27482054 | 0.80 | LMNA (0.48) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL3433562 | 0.80 | EGFR (0.42) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL12805397 | 0.80 | NR3C1 (0.44) | LMNAMAPK1HTTEGFRERBB2 | |
| SCHEMBL12401838 | 0.79 | LMNA (0.57) | LMNAMAPK1HTTKDM4EGAA | |
| SCHEMBL12175420 | 0.79 | TTR (0.55) | LMNAMAPK1HTTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2023-08-24 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-01-05 | — | — | US | disclosed |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2021-10-21 | — | — | US | disclosed |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | NEUROCRINE BIOSCIENCES, INC. | 2007-12-13 | — | — | US | disclosed |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2007-02-01 | — | — | US | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-20040152736-A1 | Thrombin receptor antagonists | TOPROL ACQUISITION LLC | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | LMNA 2905/4885MAPK1 2324/4885HTT 1027/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | LMNA 293/4885MAPK1 2498/4885HTT 1623/4885 |
| US-20070287705-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, CRH | LMNA 3501/4885MAPK1 4196/4885HTT 929/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | LMNA 2905/4885MAPK1 2324/4885HTT 1027/4885 |
| US-20230265088-A1 | The Method of the Preparation of Fused Multicyclic Compounds | CYP2W1, CYP1B1, CYP2F1 | LMNA 418/4885MAPK1 3387/4885HTT 3284/4885 |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | LMNA 3603/4885MAPK1 478/4885HTT 782/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | LMNA 2921/4885MAPK1 2157/4885HTT 2102/4885 |
| US-20040152736-A1 | Thrombin receptor antagonists | CNR1, TBXA2R, CNR2 | LMNA 2885/4885MAPK1 2416/4885HTT 3552/4885 |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | GBA1, GBA2, GAA | LMNA 1219/4885MAPK1 4023/4885HTT 1334/4885 |
| US-20230002361-A1 | 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK3, IRAK2 | LMNA 3239/4885MAPK1 847/4885HTT 3351/4885 |
| US-20210323910-A1 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | P2RX1, P2RX3, P2RX5 | LMNA 1660/4885MAPK1 1888/4885HTT 1758/4885 |
| US-20070027321-A1 | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRM1 | LMNA 4645/4885MAPK1 2462/4885HTT 2004/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | LMNA 2814/4885MAPK1 971/4885HTT 3023/4885 |
| US-20070255065-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | TBXA2R, HTR2C, NPY1R | LMNA 1931/4885MAPK1 2616/4885HTT 2224/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | LMNA 3745/4885MAPK1 356/4885HTT 2605/4885 |
| US-20070149506-A1 | Azepine inhibitors of Janus kinases | JAK1, JAK3, JAK2 | LMNA 4785/4885MAPK1 73/4885HTT 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.